Onchilles Pharma Announces Two Presentations of New Preclinical Data for N17350 and N17465 at AACR 2024

SAN DIEGO, March 6, 2024 – Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel innate immune mechanism of action, announced today it will unveil preclinical data on systemically delivered N17465 in an oral presentation and new preclinical data for tumor-directed N17350 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center.

N17350 and N17465 are first-in-class biologic therapeutics that harness the potent efficacy of the innate immune system and have the potential to become a major new treatment modality for a wide range of cancer types. The company plans to start first-in-human clinical trials for N17350 in 2024.

Presentation Details

Talk Title : N17465, a systemically deliverable elastase, attenuates tumorigenesis and stimulates anti-tumor immunity

Session : Drug Discovery 2: New Therapies
Date and Time : April 9, 2024, 2:35 PM – 2:50 PM PDT
Location : TBD
Abstract : 6578

Poster Title : N17350 kills cancer cells, spares immune cells, and regresses CDX tumors from chemotherapy-naive and experienced patients

Session : New Targets
Date and Time : April 9, 1:30 PM – 5:00 PM PDT
Location : Section 25, Board 9
Abstract Number : 5895

About N17350 and N17465 and Their Novel Mechanism of Action

First described in research published in Cell from the lab of Onchilles’ Co-Founder Lev Becker, human neutrophils release catalytically active neutrophil elastase (called ELANE), which selectively and potently kills cancer cells independent of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms. The team at Onchilles translated this ground-breaking discovery into a proprietary set of molecules, including N17350 and N17465, with the potential to treat a wide variety of tumor types with an optimal efficacy and safety profile.

About Onchilles Pharma

Onchilles Pharma is a global drug discovery and development company that leverages novel innate immuno-biology to develop the next generation of pan-cancer therapies. These first-in-class therapeutics exploit a novel fundamental mechanism of action to treat cancer independent of its genetic background or anatomical origin. The company is developing a pipeline of first-in-class biologic drug candidates and plans to start first-in-human clinical trials for its first program, N17350, in 2024 in skin cancers, head and neck cancer, and triple-negative breast cancer. For more info, visit www.onchillespharma.com.


Company : Peter Haberz, Ph.D., Vice President, Corporate Development, info@onchillespharma.com

Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091